17,620 Shares in AbbVie Inc. $ABBV Purchased by Rayburn West Financial Services LLC

Rayburn West Financial Services LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, HoldingsChannel reports. The fund acquired 17,620 shares of the company’s stock, valued at approximately $4,026,000. AbbVie makes up approximately 2.5% of Rayburn West Financial Services LLC’s portfolio, making the stock its 12th largest position.

A number of other institutional investors have also recently added to or reduced their stakes in ABBV. Chelsea Counsel Co. purchased a new stake in AbbVie during the third quarter worth about $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at about $31,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC lifted its holdings in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a report on Thursday, April 30th. Piper Sandler reduced their price objective on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $252.90.

AbbVie Stock Performance

Shares of ABBV opened at $208.39 on Thursday. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The company’s 50 day simple moving average is $211.23 and its 200 day simple moving average is $220.29. The company has a market capitalization of $368.17 billion, a price-to-earnings ratio of 102.65, a PEG ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the business posted $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities analysts expect that AbbVie Inc. will post 14.32 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio is 340.89%.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New immunology data and an upgraded 2026 earnings outlook are reinforcing confidence in AbbVie’s growth trajectory and valuation. A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
• Positive Sentiment: Analyst commentary continues to lean constructive, with recent coverage highlighting AbbVie as an attractive long-term healthcare name and pointing to a higher price target from Evercore ISI. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
• Positive Sentiment: Multiple recent articles argue AbbVie’s growth engine is “firing,” with bullish takes centered on its expanding drug portfolio and rising dividend, both supportive of investor sentiment. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
• Neutral Sentiment: AbbVie appointed Kelly Sanderson Schrems as UK VP and General Manager, a routine leadership move that is unlikely to materially move the stock on its own. AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager
• Neutral Sentiment: Shareholders backed directors and maintained the governance structure at the annual meeting, which removes uncertainty but is not a major new catalyst. AbbVie Shareholders Back Directors, Maintain Governance Structure
• Neutral Sentiment: Zacks and other commentary remain supportive, but this is mostly reinforcing existing optimism rather than introducing a major new catalyst. The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.